TiumBio CEO On Successful Partnerships, Ambitions To Develop The Next Afstyla
Multiple Clinical Assets Progressing
Executive Summary
TiumBio’s CEO shares his experiences as the original developer of hemophilia therapy Afstyla, the reason the rare disease-specialized company is exploring opportunities in Australia, as well as its R&D plans.
You may also be interested in...
Deal Watch: Denali Partners With Sirion To Take On The Blood-Brain Barrier
Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.
China Rush Over? Korean Firms Step Up To Seize Opportunities
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.
Time To Shop? SK Sees ‘Biggest Opportunity’ For Biotech Investment
At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.